PLUS1
33.12
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Iovance Biotherapeutics Inc | IOVA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 33.12 | 0.00 | 0.00 | 0.00 | 33.12 | 07:38:19 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 33.10 | 33.75 | 0.65 | 1.93% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 33.12 | USD |
Iovance Biotherapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 4.20B | 126.86M | 106.09M | $ - | $ - | -1.59 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | -3.00 | 16.40% |
Iovance Biotherapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/29/2020 | 16:24 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/29/2020 | 16:16 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 5/29/2020 | 08:01 | GlobeNewswire Inc. | Iovance Presents Updated Clinical Data for Tumor.. |
| 5/28/2020 | 21:30 | GlobeNewswire Inc. | Iovance Biotherapeutics, Inc. Announces Pricing of Its.. |
| 5/27/2020 | 17:26 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 5/27/2020 | 16:20 | GlobeNewswire Inc. | Iovance Biotherapeutics, Inc. Announces Proposed Public.. |
| 5/27/2020 | 16:15 | Edgar (US Regulatory) | Automatic Shelf Registration Statement of Securities of.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IOVA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 41.45 | 42.00 | 30.6001 | 33.29 | 4,712,460 | -8.33 | -20.1% |
| 1 Month | 32.50 | 42.00 | 30.03 | 34.41 | 2,342,137 | 0.62 | 1.91% |
| 3 Months | 33.15 | 42.00 | 18.70 | 31.87 | 2,119,359 | -0.03 | -0.09% |
| 6 Months | 23.03 | 42.00 | 18.70 | 30.27 | 1,822,617 | 10.09 | 43.81% |
| 1 Year | 17.28 | 42.00 | 16.70 | 26.48 | 1,610,791 | 15.84 | 91.67% |
| 3 Years | 5.55 | 42.00 | 4.45 | 18.56 | 1,208,271 | 27.57 | 496.76% |
| 5 Years | 10.74 | 42.00 | 4.24 | 16.77 | 864,010 | 22.38 | 208.38% |
Iovance Biotherapeutics Description
| Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. It's lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma. |
